TP53 and endometrioid adenocarcinoma: We found that women with abnormal p53 FIGO grade 3 endometrioid endometrial cancer have an increased risk of death (HR, 1.29; 95% CI, 1.11–1.48; I2 = 88%) and disease progression (HR, 1.63; 95% CI, 1.42–1.88; I2 = 2%) compared with women with wildtype p53 high-grade endometrioid carcinomas.